title: Anti-endothelial cell antibodies (AECA) in systemic sclerosis--increased sensitivity using different endothelial cell substrates and association with other autoantibodies.
abstract: OBJECTIVE
  One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. In the present study we examined whether screening of SSc patients for different anti-endothelial cells antibodies (AECA) of various origins increase the sensitivity of AECA detection in SSc patients. Secondary aim was an attempt to correlate AECA with other common autoantibodies.
  
  
  METHODS
  478 SSc patients were studied for the presence AECA, anti-cardiolipin (aCL), anti-dsDNA, anti-heparin (AHA), anti-pyruvate dehydrogenase (PDH) and anti-PDC-E2 autoantibodies. AECA levels were detemined using human umbilical vein EC (HUVEC), bone marrow EC (BMEC), EC hybridoma (EA.hy 926) and Kaposi sarcoma EC (KS).
  
  
  RESULTS
  Positive AECA were found in 49.5% of SSc patients (27.1% HUVEC; 34.3% BMEC; 26.3% EaHy 926 and 22.7% KS). The highest percent reactivity of AECA was obtained using microvascular BMEC. When combining BMEC and either other cell lines the reactivity ranged from 41.4% to 46%. A significant association between AECA on the one hand and AHA (p<0.001)) and anti-PDH (p<0.05) on the other was secn. Cross-reactivity with anti-PDC-E2 was excluded by inhibition tests, but AHA and anti-PDH may be part of the spectrum of AECA.
  
  
  CONCLUSIONS
  Since false-negative AECA may result from lack of expression of various antigens on a specific EC, analysis of AECA in SSc patients requires using several EC types, including microvascular EC.
authors.affiliation: Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors.forename: Y
authors.initials: Y
authors.lastname: Renaudineau
authors.forename: E
authors.initials: E
authors.lastname: Grunebaum
authors.forename: I
authors.initials: I
authors.lastname: Krause
authors.forename: S
authors.initials: S
authors.lastname: Praprotnik
authors.forename: R
authors.initials: R
authors.lastname: Revelen
authors.forename: P
authors.initials: P
authors.lastname: Youinou
authors.forename: M
authors.initials: M
authors.lastname: Blanks
authors.forename: B
authors.initials: B
authors.lastname: Gilburd
authors.forename: Y
authors.initials: Y
authors.lastname: Sherer
authors.forename: C
authors.initials: C
authors.lastname: Luderschmidt
authors.forename: A
authors.initials: A
authors.lastname: Eldor
authors.forename: B
authors.initials: B
authors.lastname: Weksler
authors.forename: E M
authors.initials: EM
authors.lastname: Gershwin
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D017153:Antibodies, Anticardiolipin / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis* / Q000097:blood; D002460:Cell Line; D003429:Cross Reactions; D004727:Endothelium / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods / Q000706:statistics & numerical data; D006493:Heparin / Q000276:immunology; D006801:Humans; D011768:Pyruvate Dehydrogenase Complex / Q000276:immunology; D012595:Scleroderma, Systemic / Q000276:immunology*; D012680:Sensitivity and Specificity
chemical_list: D017153:Antibodies, Anticardiolipin; D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D011768:Pyruvate Dehydrogenase Complex; C087589:anti-endothelial cell antibody; D006493:Heparin